Advertisement
U.S. markets closed
  • S&P Futures

    5,304.25
    -4.00 (-0.08%)
     
  • Dow Futures

    40,140.00
    -36.00 (-0.09%)
     
  • Nasdaq Futures

    18,465.00
    -38.75 (-0.21%)
     
  • Russell 2000 Futures

    2,145.20
    +6.80 (+0.32%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0789
    -0.0005 (-0.04%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • Vix

    13.01
    +0.23 (+1.80%)
     
  • GBP/USD

    1.2624
    +0.0001 (+0.01%)
     
  • USD/JPY

    151.4840
    +0.1120 (+0.07%)
     
  • Bitcoin USD

    70,697.69
    +1,069.23 (+1.54%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,416.78
    +248.71 (+0.62%)
     

A Trio of High Earnings Return Stocks

- By Alberto Abaterusso

If you pick securities whose earnings return is more than twice that of the 20-year high-quality market corporate bonds, you could increase your probability to unearth value opportunities, in my opinion. These bonds imply an extremely low risk of bankruptcy as they represent corporate loans issued by triple-A, double-A and single A-rated companies, and are currently granting a monthly return of 2.92% back to their holders.


Thus, investors may want to consider the following securities, as they offer earnings returns of more than 5.84% and have price-earnings ratios below 17.12.

Bio-Rad Laboratories Inc

Shares of Bio-Rad Laboratories Inc (NYSE:BIO) were trading at $621.37 per unit at close on Friday for a market capitalization of $18.3 billion.

The Hercules, California-based manufacturer and marketer of devices for clinical diagnostic and life science research organizations in North America and internationally offers an earnings return of 18.8% and has a price-earnings ratio of 5.32.

The share price has risen by 62% over the past year, determining a 52-week range of $309.38 to $648.39.

A Trio of High Earnings Return Stocks
A Trio of High Earnings Return Stocks

GuruFocus assigned a rating of 8 out of 10 for the company's financial strength and a rating of 6 out of 10 for its profitability.

Wall Street sell-side analysts recommend an overweight median rating with an average target price of $661.25 per share for this stock.

Supernus Pharmaceuticals Inc

Shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) were trading at a price of $27.26 per unit at close on Friday for a market capitalization of $1.44 billion.

The Rockville, Maryland-based pharmaceutical developer of treatments for disorders of the central nervous system offers an earnings return of 8.84% and has a price-earnings ratio of 11.31.

The stock has risen by 12.41% over the past year, determining a 52-week range of $13.12 to $27.55.

A Trio of High Earnings Return Stocks
A Trio of High Earnings Return Stocks

GuruFocus assigned a rating of 5 out of 10 to both the company's financial strength and its profitability.

Wall Street sell-side analysts recommend an overweight median rating for this stock and have established an average target price of $27.75 per share.

Five Star Senior Living Inc

Shares of Five Star Senior Living Inc (NASDAQ:FVE) were trading at $12.76 per unit at close on Friday for a market capitalization of $1.46 billion.

The Newton, Massachusetts-based operator of nearly 270 senior living communities in 32 states of the U.S. offers an earnings return of 39.84% and has a price-earnings ratio of 2.51.

The stock has risen by 49.4% over the past year for a 52-week range of $2.13 to $8.44.

A Trio of High Earnings Return Stocks
A Trio of High Earnings Return Stocks

GuruFocus assigned a rating of 7 out of 10 to the company's financial strength and a rating of 3 out of 10 to its profitability.

One sell-side analyst on Wall Street recommends a buy rating with a target price of $8.50 per share for this stock.

Disclosure: I have no positions in any securities mentioned.

Read more here:



Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.

This article first appeared on GuruFocus.

Advertisement